ASCO 2023

ASCO 2023: Novel Regimens, Improved Outcomes for Metastatic Breast Cancer

Presentations at ASCO 2023 focus on improving outcomes for patients with TNBC and HR+/HER2- metastatic breast cancer.

ASCO 2023: Studies Clarify Role of Immunotherapy in Multiple Myeloma

Studies from ASCO 2023 revealed new potential standards of care for multiple myeloma and a first for bispecific antibody therapy.

Neoadjuvant FOLFIRINOX Does Not Improve OS in Resectable Pancreatic Cancer

Neoadjuvant FOLFIRINOX does not provide a survival benefit over upfront surgery in resectable pancreatic cancer, a phase 2 study suggests.

No Benefit Seen With Adjuvant Nivolumab in Gastric/GEJ Cancer

Adding nivolumab to adjuvant chemotherapy did not improve relapse-free survival in a phase 3 trial of patients with gastric/GEJ cancer.

Telephone-Based Weight Loss Intervention Successful in Breast Cancer Survivors

Results of the Breast Cancer Weight Loss trial were presented at the 2023 ASCO Annual Meeting.